Nothing said here yet.
to join the conversation.
| EASTHAM KARINDirector | Sell | 14,850 | $742.6K | Tue, Oct 27 |
| Holstein JensDirector | Sell | 7,500 | $375.0K | Tue, Oct 27 |
| Bhanji MunaDirector | Sell | 1,864 | $81.5K | Mon, Oct 19 |
| Holstein JensDirector | Sell | 7,500 | $352.5K | Thu, Sep 24 |
| Leite JohnGlobal Chief Commercial Off | Sell | 4,015 | $160.6K | Mon, Sep 21 |
| Holstein JensDirector | Sell | 5,000 | $204.7K | Mon, Sep 14 |
| Febbo Phillip G.Chief Scientific & Med Officer | Sell | 10,405 | $446.3K | Fri, Sep 4 |
| Febbo Phillip G.Chief Scientific & Med Officer | Sell | 2,705 | $118.1K | Fri, Sep 4 |
| Chambers RebeccaChief Financial Officer | Sell | 2,477 | $106.0K | Fri, Sep 4 |
| McGuire AnnieEVP, General Counsel | Sell | 2,154 | $92.2K | Fri, Sep 4 |
| Chambers RebeccaChief Financial Officer | Sell | 1,175 | $51.4K | Fri, Sep 4 |
| McGuire AnnieEVP, General Counsel | Sell | 1,100 | $48.0K | Fri, Sep 4 |
Veracyte (VCYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veracyte reported new Phase III STAMPEDE data showing its Decipher Prostate Genomic Classifier predicted which very high-risk nonmetastatic prostate cancer patients benefited most from adding abiraterone to androgen deprivation therapy, with larger…
Veracyte (VCYT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Veracyte has seen its stock build a long upward track record, and the question now is whether the current share price lines up with the cash flows the business is expected to generate.
Veracyte (VCYT) is back in focus after new phase III data on its Decipher Prostate Genomic Classifier showed it can help identify which intermediate-risk prostate cancer patients benefit most from adding short-term hormone therapy.
Veracyte, Inc. recently presented retrospective ancillary Phase III NRG/RTOG 0815 trial data at the 2026 ASTRO meeting, showing that its Decipher Prostate Genomic Classifier can stratify which intermediate-risk prostate cancer patients benefit from adding short-term androgen deprivation therapy to dose-escalated radiation, with Level 1B1 prognostic and predictive evidence.